Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus

By E. Selvin, S. Marinopoulos, G. Berkenblit, T. Rami, F. Brancati, N. Powe, S. Golden. Annals of Internal Medicine, 2004

1,726 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/6a7701abd505823cbd668cc2ef9175fe9bc24368

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. V. Basevi
2. D. Nathan
3. John B. Buse
4. K. ‐. Tseng
5. G. Bakris
6. Å. Lernmark
7. J. Forbes
8. E. Gale

In Molecular Biology

1. V. Basevi
2. K. ‐. Tseng
3. D. Nathan
4. J. Forbes
5. M. Cooper
6. John B. Buse

Citations in the corpus

• Meta-Analysis: Chronic Disease Self-Management Programs for Older Adults (2005, background): “81%, a change that is strongly associated with all-cause and cardiovascular mortality in observational studies (84, 85).”
• Standards of Medical Care in Diabetes–2006 (2006, background): “The potential of intensive glycemic control to reduce CVD is supported by epidemiological studies (25–30) and a recent meta-analysis (31), but this potential benefit on CVD events has not yet been demonstrated in a randomized clinical trial.”
• Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2002, background): “Although meta-analyses have suggested that intensive glycemic control reduces cardiovascular disease in individuals with type 2 diabetes (47,48), clinical trials have not consistently demonstrated a reduction in macrovascular disease (myocardial infarction or stroke) with intensive therapy aimed at ”
• Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. (2002, background): “Although meta-analyses have suggested that intensive glycemic control reduces cardiovascular disease in individuals with type 2 diabetes (47,48), clinical trials have not consistently demonstrated a reduction in macrovascular disease (myocardial infarction or stroke) with intensive therapy aimed at ”
• Dissemination and publication of research findings: an updated review of related biases. (2010, result): “Comparison of studies published in different languages Egger et al. (1997)148 identified 40 pairs of RCTs, each pair comprising an RCT published in German, and a matched RCT by the same author published in English during the same period.”
• Standards of Medical Care in Diabetes—2008 (2008, background): “The potential of intensive glycemic control to reduce CVD in type 2 diabetes is supported by epidemiological studies (31,40–42) and a meta-analysis (43), but has not yet been demonstrated in a randomized clinical trial.”
• Standards of Medical Care in Diabetes—2012 (2011, background): “The potential of intensive glycemic control to reduce CVD is supported by epidemiological studies (22–27) and a recent meta-analysis (28), but this potential benefit on CVD events has not yet been demonstrated in a randomized clinical trial.”
• Effects of Aerobic Training, Resistance Training, or Both on Glycemic Control in Type 2 Diabetes (2007, background): “A 1% absolute decrease in the hemoglobin A1c value is associated with a 15% to 20% decrease in major cardiovascular events (5) and a 37% reduction in microvascular complications (6).”
• Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials (2009, background): “Whereas many epidemiologic studies and metaanalyses (7,8) have clearly shown a direct relationship between A1C and CVD, the potential of intensive glycemic control to reduce CVD events has been less clearly defined.”